|Bid||80.04 x 800|
|Ask||127.00 x 800|
|Day's Range||88.57 - 93.42|
|52 Week Range||74.31 - 121.11|
|Beta (5Y Monthly)||0.83|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 28, 2020 - May 03, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||132.44|
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The biotechnology industry is comprised of hundreds of companies that fuse biology and technology to develop drugs and related products for the treatment of diseases and medical conditions. Today's biotechnology industry includes companies that make medical devices and diagnostics, as well as biofuels, biomaterials, pollution controls, and more.
United Therapeutics (UTHR) delivered earnings and revenue surprises of -51.42% and -11.10%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
United Therapeutics Corporation (Nasdaq: UTHR) announced today that Michael Benkowitz, President and Chief Operating Officer of United Therapeutics, will participate in a fireside chat covering the company's business at the 40th Annual Cowen & Company Healthcare Conference in Boston, Massachusetts.
It’s a good day for United Therapeutics Corp. The Silver Spring biotech announced Monday its pulmonary arterial hypertension treatment, Tyvaso, essentially passed its clinical tests among patients with interstitial lung disease — a bright spot after the company faced back-to-back failed late-stage trials in both a cancer therapy and a different PAH product in the last year-plus. The phase 3 trial, per a preliminary analysis, demonstrated that 16 weeks of treatment with Tyvaso was effective in increasing the distance, by 21 meters, that patients could walk in six minutes when compared with a placebo. The news sent the company's stock rising nearly 7% in Monday afternoon trading to $114.41 per share by about 1:45 p.m. Tyvaso could fill a major unmet medical need — there are currently no approved therapies for the roughly 30,000 PAH patients with interstitial lung disease, which causes scarring of the lungs and hinders breathing.
United Therapeutics Corporation (Nasdaq: UTHR) and DEKA Research & Development Corp. today announced receipt of an additional 510(k) clearance by the U.S. Food and Drug Administration (FDA) related to the Unity Subcutaneous Delivery System for Remodulin® (treprostinil) Injection, also referred to as the Remunity™ pump, enabling United Therapeutics to launch the system using drug reservoirs that have been prefilled by specialty pharmacies.
United Therapeutics Corporation (NASDAQ: UTHR) today announced that preliminary analysis indicates that the INCREASE clinical study of Tyvaso® (treprostinil) Inhalation Solution in patients suffering from World Health Organization (WHO) Group 3 pulmonary hypertension associated with interstitial lung disease (PH-ILD) has met its primary efficacy endpoint of demonstrating improvement in six-minute walk distance (6MWD).
United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: Tempur Sealy International, Twin River Worldwide, Rite Aid, DaVita and United Therapeutics
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2019 financial results before the market opens on Wednesday, February 26, 2020.
A federal has denied an injunction motion from Sandoz and RareGen, the companies selling a generic form of a drug that United Therapeutics had under patent until early 2019.